9 completed, 3 terminated, 2 recruiting, 2 unknown. 17 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 9, Terminated 3, Recruiting 2, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 9 | Completed 4, Terminated 2, Unknown 2, Recruiting 1 |
Follow Riluzole: new trials by email Literature Review of Riluzole trials Research Report on Riluzole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients Masitinib 4.5 mg/kg/day, Placebo, Riluzole (100 mg) - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Not yet recruiting | AB Science | 412 | 2026-01-01 | 2025-10-03 |
| Riluzole in Patients With Spinocerebellar Ataxia Type 7 Riluzole, Placebo - SCA7 | Phase 2 / Phase 3 | Recruiting | S. Andrea Hospital | 34 | 2021-06-01 | 2024-12-02 |
| Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS Lenzumestrocel, Riluzole, Placebo Comparator - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Corestemchemon, Inc. | 123 | 2021-02-24 | 2026-04-30 |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Masitinib (6.0), Riluzole, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Recruiting | AB Science | 495 | 2021-02-02 | 2025-09-12 |
| The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules Huolingshengji Granules, Riluzole tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Unknown | Peking University Third Hospital | 144 | 2020-06-01 | 2021-07-08 |
| Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Riluzole, Placebo - Spinocerebellar Ataxia Type 2 | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 42 | 2018-01-17 | 2021-06-21 |
| Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) Edaravone, Riluzole - Neuromuscular Diseases | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 20 | 2017-03-16 | 2019-03-27 |
| Riluzole in Spinal Cord Injury Study Riluzole, Placebo - Spinal Cord Injury | Phase 2 / Phase 3 | Terminated | AOSpine North America Research Network | 193 | 2013-10-01 | 2021-04-19 |
| Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Masitinib (4.5), Riluzole, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | AB Science | 394 | 2013-04-01 | 2023-09-29 |
| Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) riluzole, Placebo medication - Cervical Spondylotic Myelopathy | Phase 3 | Completed | AOSpine North America Research Network | 270 | 2012-03-01 | 2018-11-02 |
| Efficacy of Riluzole in Hereditary Cerebellar Ataxia riluzole, Placebo comparator - Cerebellar Ataxia | Phase 2 / Phase 3 | Completed | S. Andrea Hospital | 60 | 2010-04-01 | 2015-04-21 |
| Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS Olesoxime, Placebo Comparator, Riluzole - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 512 | 2009-04-30 | 2020-02-25 |
| Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Lithium Carbonate, Riluzole, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Terminated | Massachusetts General Hospital | 84 | 2009-01-01 | 2011-04-19 |
| Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA) Riluzole - SMA | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 141 | 2006-01-01 | 2013-02-15 |
| Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) Memantine (Ebixa), riluzole, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University of Lisbon | 63 | 2005-07-01 | 2009-04-01 |
| Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Riluzole - Multiple System Atrophy, Progressive Supranuclear Palsy | Phase 3 | Terminated | King's College London | 800 | 2000-04-01 | 2005-12-15 |
| Riluzole in Huntington's Disease Riluzole - Huntington Disease | Phase 3 | Completed | Sanofi | 537 | 1999-11-01 | 2012-02-17 |
Amyotrophic Lateral Sclerosis (9) · Motor Neuron Disease (2) · Spinocerebellar Ataxias (2) · Cerebellar Ataxia (1) · Friedreich Ataxia (1) · Huntington Disease (1) · Multiple System Atrophy (1) · Nerve Degeneration (1) · Neuromuscular Diseases (1) · Spinal Cord Injuries (1) · Supranuclear Palsy, Progressive (1)
AB Science (3) · AOSpine North America Research Network (2) · Assistance Publique - Hôpitaux de Paris (2) · S. Andrea Hospital (2) · Corestemchemon, Inc. (1) · Hoffmann-La Roche (1) · Isfahan University of Medical Sciences (1) · King's College London (1) · Massachusetts General Hospital (1) · Peking University Third Hospital (1) · Sanofi (1) · University of Lisbon (1)
France (4) · United States (4) · Canada (3) · Italy (3) · Spain (3) · Belgium (2) · Germany (2) · Greece (2) · Portugal (2) · United Kingdom (2) · Australia (1) · China (1) · Denmark (1) · Iran (1) · Israel (1)
Albert Ludolph, MD, PhD (1) · Branko Kopjar, MD (1) · Branko Kopjar, MD, PhD (1) · Dongsheng Fan (1) · Jesus S Mora, MD (1) · Jinsy Andrews, MD (1) · Lorne Zinman, MD, MSc, FRCPC (1) · Mamede de Carvalho, MD (1) · Merit Cudkowicz, MD, MSc (1) · Michael Fehlings, MD (1) · Michael Fehlings, MD, PhD (1)
PMID 19029129, PMID 19771175, PMID 20363190, PMID 21386111, PMID 21829612, PMID 22985379, PMID 23295632, PMID 26321318, PMID 26394202, PMID 26714284, PMID 30814647, PMID 33357512, PMID 34433481, PMID 34457038, PMID 35063116, PMID 35585556, PMID 36048877, PMID 37130044, PMID 37279301, PMID 37794802, PMID 38011420, PMID 38197642, PMID 39446982, PMID 40347099, PMID 41086299
2017 (1), U01NS049640 (1)